192 related articles for article (PubMed ID: 27926979)
1. Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome.
Garelius HK; Johnston WT; Smith AG; Park S; de Swart L; Fenaux P; Symeonidis A; Sanz G; Čermák J; Stauder R; Malcovati L; Mittelman M; van de Loosdrecht AA; van Marrewijk CJ; Bowen D; Crouch S; de Witte TJ; Hellström-Lindberg E
J Intern Med; 2017 Mar; 281(3):284-299. PubMed ID: 27926979
[TBL] [Abstract][Full Text] [Related]
2. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.
Duong VH; Baer MR; Hendrick F; Weiss SR; Sato M; Zeidan AM; Gore SD; Davidoff AJ
Leuk Res; 2015 Jun; 39(6):586-91. PubMed ID: 25869077
[TBL] [Abstract][Full Text] [Related]
3. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
[TBL] [Abstract][Full Text] [Related]
4. Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients.
Park S; Kelaidi C; Sapena R; Vassilieff D; Beyne-Rauzy O; Coiteux V; Vey N; Ravoet C; Cheze S; Rose C; Legros L; Stamatoullas A; Escoffre-Barbe M; Guerci A; Chaury MP; Fenaux P; Dreyfus F
Leuk Res; 2010 Nov; 34(11):1430-6. PubMed ID: 20580086
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
[TBL] [Abstract][Full Text] [Related]
6. Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
Tsang E; Leitch HA
Ann Hematol; 2016 Jan; 95(1):73-78. PubMed ID: 26453076
[TBL] [Abstract][Full Text] [Related]
7. Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.
Buccisano F; Piccioni AL; Nobile C; Criscuolo M; Niscola P; Tatarelli C; Fianchi L; Villivà N; Neri B; Carmosino I; Gumenyuk S; Mancini S; Voso MT; Maurillo L; Breccia M; Zini G; Venditti A; Fenu S; Spiriti MA; Latagliata R;
Ann Hematol; 2016 Jun; 95(7):1059-65. PubMed ID: 27091349
[TBL] [Abstract][Full Text] [Related]
8. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
9. Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes.
Mundle SD
Future Oncol; 2007 Aug; 3(4):397-403. PubMed ID: 17661714
[TBL] [Abstract][Full Text] [Related]
10. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
Itzykson R; Thépot S; Beyne-Rauzy O; Ame S; Isnard F; Dreyfus F; Salanoubat C; Taksin AL; Chelgoum Y; Berthon C; Malfuson JV; Legros L; Vey N; Turlure P; Gardin C; Boehrer S; Ades L; Fenaux P;
Leuk Res; 2012 Apr; 36(4):397-400. PubMed ID: 22177456
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.
Hattakitpanitchakul S; Kobbuaklee S; Wudhikarn K; Polprasert C
Asian Pac J Cancer Prev; 2021 Dec; 22(12):4037-4042. PubMed ID: 34967586
[TBL] [Abstract][Full Text] [Related]
12. Impact of transfusion on survival in patients with myelodysplastic syndromes: Current knowledge, new insights and transfusion clinical practice.
Kaphan E; Laurin D; Lafeuillade B; Drillat P; Park S
Blood Rev; 2020 May; 41():100649. PubMed ID: 31918886
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review.
Park S; Greenberg P; Yucel A; Farmer C; O'Neill F; De Oliveira Brandao C; Fenaux P
Br J Haematol; 2019 Jan; 184(2):134-160. PubMed ID: 30549002
[TBL] [Abstract][Full Text] [Related]
14. Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.
Hendrick F; Davidoff AJ; Zeidan AM; Gore SD; Baer MR
Medicare Medicaid Res Rev; 2014; 4(4):. PubMed ID: 25485173
[TBL] [Abstract][Full Text] [Related]
15. No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki.
Toriyama E; Hata T; Yokota KI; Chiwata M; Kamijo R; Hashimoto M; Taguchi M; Horai M; Matsuo M; Matsuo E; Takasaki Y; Kawaguchi Y; Itonaga H; Sato S; Ando K; Sawayama Y; Taguchi J; Imaizumi Y; Tsushima H; Jo T; Yoshida S; Moriuchi Y; Miyazaki Y
Cancer Sci; 2020 Dec; 111(12):4490-4499. PubMed ID: 32939867
[TBL] [Abstract][Full Text] [Related]
16. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
17. The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromes.
Raimbault A; Itzykson R; Willems L; Rousseau A; Chapuis N; Mathis S; Clauser S; Radford-Weiss I; Bouscary D; Fontenay M; Kosmider O; Bardet V
Cytometry B Clin Cytom; 2019 May; 96(3):215-222. PubMed ID: 30963682
[TBL] [Abstract][Full Text] [Related]
18. Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent hemoglobin levels and transfusions in hemodialysis patients.
Wong BC; Ravani P; Manns BJ; Lewin A; Zhang X; Chin R; Hemmelgarn BR; Tonelli M; Oliver MJ; Quinn RR
Am J Kidney Dis; 2013 Nov; 62(5):947-52. PubMed ID: 23856380
[TBL] [Abstract][Full Text] [Related]
19. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
Ma X; Steensma DP; Scott BL; Kiselev P; Sugrue MM; Swern AS
BMJ Open; 2018 Jul; 8(7):e019955. PubMed ID: 30037860
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).
Almeida A; Fenaux P; List AF; Raza A; Platzbecker U; Santini V
Leuk Res; 2017 Jan; 52():50-57. PubMed ID: 27883945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
